Share Name Share Symbol Market Type Share ISIN Share Description
Aortech International LSE:AOR London Ordinary Share GB0033360586 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +1.00p +2.38% 43.00p 40.00p 46.00p 43.00p 42.00p 42.00p 39,947 11:32:47
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.6 -0.2 -4.3 - 2.39

Aortech Share Discussion Threads

Showing 4151 to 4175 of 4175 messages
Chat Pages: 167  166  165  164  163  162  161  160  159  158  157  156  Older
DateSubjectAuthorDiscuss
18/1/2018
09:33
Is it 'ignorant' to say 'let's wait for what the knowledgeable insiders tell us' ?
the stigologist
18/1/2018
09:21
I see you only define negative views as "hopeless ignorant speculation" not your own "positive" hopeless ignorant speculation.
harrogate
18/1/2018
09:16
Only the Management know the true situation. Each contractual licence will have it's own specific terms with those particular counterparties. Being 'Monday morning' Quarterbacks on here is a futile exercise. Let them get on with it rather than spouting hopeless ignorant speculation.
the stigologist
18/1/2018
09:06
I take back the no new licences point - apologies. The rest stands and I think anyone on here hoping for short good news will be sadly disappointed.
harrogate
18/1/2018
09:01
Why not read an RNS before embarrassing yourself harrogate? "A new revenue-generating licence has been signed and enquiries have increased markedly. "
the stigologist
18/1/2018
08:57
mikeh30 - I suggest that you go back over the last 5+ years and read the statements. They have always been about to sign new licences with lots of people evaluating the material. Have they cancelled any other licences other than the one they gave a few years ago to a weird Latin American company.
harrogate
18/1/2018
08:54
The licenses are granted to companies who, in simple terms, incorporate the AOR technology into their products and then sell the products and AOR receive license fees. AOR also have an agreement with a third party who produce elast-eon for sale to third parties and AOR benefit financially from these sales. AOR have no capacity themselves to manufacture and produce no products therefore licenses terminated = no income for AOR. There should certainly be a review of existing licenses to see if greater income can be generated It is to be hoped that the review will also identify ways of increasing AOR income by identifying existing unused/underused AOR intellectual property and putting together a strategy for bringing a product to market which incorporates that technology. It is difficult to see AOR doing this on a stand alone basis due to lack of employees and lack of financial clout In addition, taking a product to market does not happen overnight, especially in the medical field, therefore cash is required from other sources ie license fees, to meet day to day requirements. It would be great to see new license agreements announced, for example breast enhancements, where AOR have recently got ownership of their technology back It is hoped that the next RNS from AOR will update on these points and hopefully identify a strategy going forward which will see the clearly excellant technology owned by AOR, being monitised for the benefit of shareholders Edit - written before i saw your post harrogate and I agree, in the main, with your comments
25october1969
18/1/2018
08:51
Also using Elast-eon in the cosmetic field amongst other areas. They have recently recalled some licenses. These are the ones that can be re-assigned so yes we do know where new licenses can come from It's pretty clear from their statements
mikeh30
18/1/2018
08:48
I am not sure why anyone thinks that suddenly lots more licences will be signed in the short term? Biomerics have the technology and it can't be brought back in house as we have no facilities, staff or expertise. We are in essence a virtual company that relies on Biomerics to promote our technology. As far as we know and I am sure it would have been trumpeted, they have signed no new licences for our material for a good while. Even when someone might be interested and are thus evaluating the material it takes years to get it applied to the product, approved and into the market and thus to start providing an income for us. The key here as I have said for years is the heart valve - the development of synthetic heartvalves has taken off and if our technology still has validity for this market - it is nearly 20 years old now - we could get some real excitement from this. But any development of this will need cash and it will be all about the structure and dilution involved in that inevitable fundraise.
harrogate
18/1/2018
08:36
""There are currently a number of companies evaluating Elast-Eon(TM) which if succesful may lead to other licences.""
mikeh30
18/1/2018
08:22
Exactly Roy. This is the path to take & hopefully more to follow.
cocker
18/1/2018
08:12
Just a question, would this not generate more income?
mustau
18/1/2018
08:04
mustau -Why would they terminate licenes, which is their only income stream, and bring back in house?
25october1969
18/1/2018
07:47
Normally internal reviews tend to have a guideline of 3/6 months. Unless they started before dec 17, conclusion in March. Not expecting a fund raise but this is aim!
mustau
18/1/2018
07:41
Why March? . I anticipate that news will come asap with details of how to best utilise AOR's intellectual property. My only concern is that when it does come, its not accompanied with some sort of fund raise at a reduced price to give AOR a cash injection.
cocker
17/1/2018
21:37
Not expecting anything until at least March, hopefully review concluded. What chance of terminating licences and bring back in-house?
mustau
17/1/2018
21:10
Not sure it's worth the wait for a price 5p or so better. If there's a decent RNS it'll be 11th Dec all over again and very hard to buy a decent quantity. I topped up this afternoon (nice of them to drop it for me) - that's me done for now.
verulamium
17/1/2018
19:45
Yep, it might go a tad lower to test mid to late 30's but then a great buying opp.
k1ngkonggb
17/1/2018
19:43
Without news only one way unfortunately.
mustau
17/1/2018
15:30
Chart still intact but could go either way big time.
cocker
15/1/2018
17:49
I’ll be happy with the tens first!! Let’s hsve some news.
mustau
15/1/2018
13:15
I wouldn't even bother trying to put an upside capping number on it yet until they reveal their strategic plan but the sense I get is hundreds of millions not mere tens
the stigologist
15/1/2018
13:05
If they can Re-negotiate some of their existing licenses and add new licensees with higher % fees we could easily be looking at a 10-20m Mcap.There is obvious value here, now the litigation is over and cash position improving, it's time to see if they can exploit their new found free time and expertise.Literally, my money is on them succeeding. I'm expecting, at any time, a strategic review with news of new licensees and renegotiated fees. 100p to start.Aimho dyor etc ...
mikeh30
12/1/2018
17:06
I have a feeling Roy's a jock, in which case he is more than capable of tossing his own cabor.
cocker
12/1/2018
16:12
Were you two together last night then ?
the stigologist
Chat Pages: 167  166  165  164  163  162  161  160  159  158  157  156  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20180118 23:42:40